Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

20260 citationsJournal Articlegold Open Access

Authors

Stephen Lam Chan · Chinese University of Hong Kong

Thomas Yau · Education University of Hong Kong

R. K. Kelley · University of California, San Francisco

Richard S. Finn · University of California, Los Angeles

Changhoon Yoo · Ulsan College

Junji Furuse · Kyorin University Hospital

Ren Zheng-gang

Abstract

Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.

Topics & Keywords

Cholangiocarcinoma and Gallbladder Cancer Studies Hepatocellular Carcinoma Treatment and Prognosis Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Research Communications

Volume 6, Issue 3, pp. 577-584

DOI: 10.1158/2767-9764.crc-25-0633

Field-Weighted Citation Impact: 0.00